ADHD stimulant prodrug versus stimulant prodrug/mixture
Vyvanse is lisdexamfetamine, a prodrug of dextroamphetamine. [1] Azstarys is a fixed-dose combination of serdexmethylphenidate (a prodrug of dexmethylphenidate) plus dexmethylphenidate. [2]
Active ingredient type
Vyvanse (lisdexamfetamine)
- Lisdexamfetamine is converted to active dextroamphetamine in the body. [1]
- Vyvanse is a central nervous system stimulant. [1]
Azstarys (serdexmethylphenidate/dexmethylphenidate)
- Azstarys contains serdexmethylphenidate plus dexmethylphenidate in a fixed ratio. [2]
- Azstarys is a central nervous system stimulant. [2]
FDA-approved indications and age limits
Vyvanse
- Vyvanse is indicated for the treatment of ADHD. [1]
- Vyvanse is indicated for moderate-to-severe binge eating disorder in adults. [1]
Azstarys
- Azstarys is indicated for the treatment of ADHD in patients 6 years of age and older. [2]
Dosing schedule and controlled-substance status
Vyvanse
- Vyvanse is designated as a Schedule CII controlled substance. [1]
Azstarys
- Azstarys is designated as a Schedule CII controlled substance. [2]
Pharmacokinetics and onset profile
Vyvanse
- After a single dose of 60 mg Vyvanse chewable tablet under fasted conditions, time to peak plasma concentration (Tmax) of lisdexamfetamine is approximately 1 hour. [3]
- After a single dose of 60 mg Vyvanse chewable tablet under fasted conditions, Tmax of dextroamphetamine is approximately 4.4 hours. [3]
- Plasma elimination half-life of dextroamphetamine is approximately 8.6 to 9.5 hours in pediatric patients 6 to 12 years and 10 to 11.3 hours in healthy adults. [4]
Azstarys
- After a single dose of Azstarys under fasted conditions, median Tmax for serdexmethylphenidate and dexmethylphenidate is about 2 hours. [5]
- Following a single dose of 52.3 mg/10.4 mg Azstarys, mean terminal elimination half-life is about 5.7 hours for serdexmethylphenidate and about 11.7 hours for dexmethylphenidate. [6]
Clinical implications of the drug delivery systems
Vyvanse
- Vyvanse is designed as a prodrug strategy that delays conversion to the active dextroamphetamine exposure, consistent with a later Tmax for dextroamphetamine relative to lisdexamfetamine. [3]
Azstarys
- Azstarys is designed with serdexmethylphenidate that is converted to active dexmethylphenidate, producing a methylphenidate-based exposure profile with a relatively later Tmax for the methylphenidate moiety compared with immediate-release formulations. [5]
Key adverse-effect risk considerations reflected in labeling
Common stimulant class warnings
- Both products carry abuse and misuse warnings consistent with stimulant class risk. [1] [2]
Practical differentiation points in selection
When selecting a medication based on indication
- Vyvanse selection may be favored when binge eating disorder (moderate-to-severe) is an additional target indication in adults. [1]
- Azstarys selection is restricted to ADHD per its FDA-labeled indication. [2]
When selecting a medication based on population eligibility
- Azstarys selection is limited to patients age 6 years and older per FDA labeling. [2]
- Vyvanse is indicated for ADHD across pediatric and adult populations per its FDA labeling. [1]
When selecting a medication based on exposure timing
- Vyvanse produces dextroamphetamine Tmax around 4.4 hours after a 60 mg chewable dose under fasted conditions. [3]
- Azstarys produces median Tmax around 2 hours for the serdexmethylphenidate/dexmethylphenidate components under fasted conditions. [5]
Summary of the major differences
Vyvanse delivers amphetamine-family activity via conversion of lisdexamfetamine to dextroamphetamine. [1] Azstarys delivers methylphenidate-family activity via conversion of serdexmethylphenidate to dexmethylphenidate plus co-formulated dexmethylphenidate. [2]